Scott E. Counts
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Scott E. Counts has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
Elliott J. Mufson
Department of Translational Neurosciences, Barrow Neurological Institute, Phoenix, AZ, USA
12 shared publicationsJohn S. Beck
Departments of Translational Neuroscience and Family Medicine, Michigan State University, Grand Rapids, MI, USA
8 shared publicationsBin He
Department of Translational Neurosciences, Barrow Neurological Institute, Phoenix, AZ, USA
7 shared publications- Stephen D. Ginsberg
Center for Dementia Research, Nathan Kline Institute, Orangeburg, NY 10962, USA; Department of Psychiatry, New York University Grossman School of Medicine, New York, NY 10016, USA; Department of Neuroscience & Physiology, New York University Grossman School of Medicine, New York, NY 10016, USA; NYU Neuroscience Institute, New York University Grossman School of Medicine, New York, NY 10016, USA
5 shared publications - Elliott Jay Mufson
Department of Translational Neuroscience Barrow Neurological Institute Phoenix Arizona USA
4 shared publications Anne M. Dorrance
Michigan State University
3 shared publications
Latest Publications
- 16 October 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
Locus coeruleus degeneration impairs forebrain arteriole physiology and perfusion in a rat model of Alzheimer's disease
The locus coeruleus (LC) provides forebrain norepinephrine (NE) and degenerates early in Alzheimer's disease (AD). We have shown that experimental LC lesions in the Tg344-19 AD rat model result in parenchymal arteriole (PA) stenosis, blood-brain barrier permeability, amyloid angiopathy, and cognitive impairment. Here, we show that PAs from LC-lesioned Tg344-19 AD rats displayed increased myogenic tone and decreased responsiveness to TRPV4 channel agonists, which was reversible by NE replacement. MRI studies indicated reduced forebrain perfusion and fractional anisotropy in LC-lesioned animals compared to controls. Targeting LC-mediated effects on cerebral hemodynamics presents a compelling AD therapeutic target.
- 16 October 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
Locus coeruleus degeneration impairs forebrain arteriole physiology and perfusion in a rat model of Alzheimer's disease
The locus coeruleus (LC) provides forebrain norepinephrine (NE) and degenerates early in Alzheimer's disease (AD). We have shown that experimental LC lesions in the Tg344-19 AD rat model result in parenchymal arteriole (PA) stenosis, blood-brain barrier permeability, amyloid angiopathy, and cognitive impairment. Here, we show that PAs from LC-lesioned Tg344-19 AD rats displayed increased myogenic tone and decreased responsiveness to TRPV4 channel agonists, which was reversible by NE replacement. MRI studies indicated reduced forebrain perfusion and fractional anisotropy in LC-lesioned animals compared to controls. Targeting LC-mediated effects on cerebral hemodynamics presents a compelling AD therapeutic target.
- Open Access
- 25 September 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (10) , 1518
Changes in Adrenergic and Cholinergic Receptors on Human Cerebral Vessels
Background/Objectives: Sporadic cerebral amyloid angiopathy (CAA) occurs due to a failure of clearance of amyloid-beta (Aβ) along the walls of capillaries and arteries. Soluble Aβ is eliminated from the brain along the basement membranes of capillaries and arteries as Intramural Periarterial Drainage (IPAD). The motive force for IPAD is provided by the spontaneous contractions of vascular smooth muscle cells, as vasomotion. Cerebrovascular smooth muscle cells receive adrenergic and cholinergic innervation from the Locus Coeruleus and the Nucleus Basalis of Meynert, which are compromised very early in Alzheimer’s disease (AD). Here, we tested the hypothesis that adrenergic and cholinergic receptors are histologically preserved in parenchymal and leptomeningeal blood vessels with CAA. Methods: Using immunohistochemistry, we examined the cerebrovascular distribution of muscarinic (M1, M2), nicotinic (α 7 nicotinic acetylcholine receptor), and adrenergic (α1b/2b) receptors in post-mortem brain tissue. We compared receptor distribution across CAA and non-CAA patients, as well as young and old patients without CAA. Results: We found significant differences in the receptor immunoreactivity of α7 nicotinic acetylcholine receptors, as well as α1b and α2b adrenergic receptors. However, there were no differences in the receptor immunoreactivity of M1 or M2 muscarinic receptors between patient groups. Conclusions: As IPAD depends on the functionality of the vascular smooth muscle cells to maintain the integrity of IPAD with aging, based on these histological findings, future therapeutic interventions could focus on agonists of α7 nicotinic acetylcholine and α1b/2b adrenergic receptors.
- 25 September 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (10) , 1518
Open AccessChanges in Adrenergic and Cholinergic Receptors on Human Cerebral Vessels
Background/Objectives: Sporadic cerebral amyloid angiopathy (CAA) occurs due to a failure of clearance of amyloid-beta (Aβ) along the walls of capillaries and arteries. Soluble Aβ is eliminated from the brain along the basement membranes of capillaries and arteries as Intramural Periarterial Drainage (IPAD). The motive force for IPAD is provided by the spontaneous contractions of vascular smooth muscle cells, as vasomotion. Cerebrovascular smooth muscle cells receive adrenergic and cholinergic innervation from the Locus Coeruleus and the Nucleus Basalis of Meynert, which are compromised very early in Alzheimer’s disease (AD). Here, we tested the hypothesis that adrenergic and cholinergic receptors are histologically preserved in parenchymal and leptomeningeal blood vessels with CAA. Methods: Using immunohistochemistry, we examined the cerebrovascular distribution of muscarinic (M1, M2), nicotinic (α 7 nicotinic acetylcholine receptor), and adrenergic (α1b/2b) receptors in post-mortem brain tissue. We compared receptor distribution across CAA and non-CAA patients, as well as young and old patients without CAA. Results: We found significant differences in the receptor immunoreactivity of α7 nicotinic acetylcholine receptors, as well as α1b and α2b adrenergic receptors. However, there were no differences in the receptor immunoreactivity of M1 or M2 muscarinic receptors between patient groups. Conclusions: As IPAD depends on the functionality of the vascular smooth muscle cells to maintain the integrity of IPAD with aging, based on these histological findings, future therapeutic interventions could focus on agonists of α7 nicotinic acetylcholine and α1b/2b adrenergic receptors.
- Open Access
- 18 September 2026
- Published by Wiley in British Journal of Pharmacology
Bioengineered microbiotic levodopa therapy improves cognition and reduces pathology in a rat model of Alzheimer's disease
Background and Purpose: Degeneration of the pontine noradrenergic and midbrain dopaminergic systems contributes to cognitive‐behavioural disturbances during the prodromal stages of Alzheimer's disease (AD). We developed a genetically engineered, programmable probiotic Escherichia coli Nissle 1917 strain (EcN rha L‐DOPA ) capable of producing L‐3,4‐dihydroxyphenylalanine (L‐DOPA) in a sustained and titratable manner, thus offering a novel gut‐brain delivery mechanism to increase brain levels of noradrenaline and dopamine during the early stages of AD. Experimental Approach: We replicated locus coeruleus (LC) projection system degeneration in AD by administering dopamine‐ β ‐hydroxylase IgG‐saporin immunotoxin into the prefrontal cortex of 6‐months‐old Tg344‐19 AD rats. The animals then received EcN rha L‐DOPA /benserazide or placebo by daily gavage for 6 weeks. We assessed cognitive‐behavioural function prior to postmortem assessments of amyloid‐β plaque load, glial cell activation and neuronal and synaptic markers. Gut colonization, along with plasma and brain L‐DOPA, dopamine, noradrenaline and metabolite levels, were also measured. Key Results: EcN rha L‐DOPA displayed stable gut colonization and resulted in sustained therapeutic levels of L‐DOPA in plasma and brain, resulting in increased cortical and hippocampal noradrenaline levels. EcN rha L‐DOPA reduced anxiety‐like behaviour improved spatial and working memory. The treatment reduced forebrain A β plaque and MHC‐II antigen‐presenting microglial load. Additionally, EcN rha L‐DOPA increased protein levels of the dendritic spine marker PSD95. Conclusions and Implications: This translational study suggests that EcN rha L‐DOPA modifies AD by boosting brain catecholamine production, reducing A β accumulation and neuroinflammation, promoting synaptic health, and enhancing cognitive function. Collectively, these results highlight EcN rha L‐DOPA as a promising preclinical engineered gut microbiome‐based therapeutic strategy for early‐stage AD.
- 18 September 2026
- Published by Wiley in British Journal of Pharmacology
Open AccessBioengineered microbiotic levodopa therapy improves cognition and reduces pathology in a rat model of Alzheimer's disease
Background and Purpose: Degeneration of the pontine noradrenergic and midbrain dopaminergic systems contributes to cognitive‐behavioural disturbances during the prodromal stages of Alzheimer's disease (AD). We developed a genetically engineered, programmable probiotic Escherichia coli Nissle 1917 strain (EcN rha L‐DOPA ) capable of producing L‐3,4‐dihydroxyphenylalanine (L‐DOPA) in a sustained and titratable manner, thus offering a novel gut‐brain delivery mechanism to increase brain levels of noradrenaline and dopamine during the early stages of AD. Experimental Approach: We replicated locus coeruleus (LC) projection system degeneration in AD by administering dopamine‐ β ‐hydroxylase IgG‐saporin immunotoxin into the prefrontal cortex of 6‐months‐old Tg344‐19 AD rats. The animals then received EcN rha L‐DOPA /benserazide or placebo by daily gavage for 6 weeks. We assessed cognitive‐behavioural function prior to postmortem assessments of amyloid‐β plaque load, glial cell activation and neuronal and synaptic markers. Gut colonization, along with plasma and brain L‐DOPA, dopamine, noradrenaline and metabolite levels, were also measured. Key Results: EcN rha L‐DOPA displayed stable gut colonization and resulted in sustained therapeutic levels of L‐DOPA in plasma and brain, resulting in increased cortical and hippocampal noradrenaline levels. EcN rha L‐DOPA reduced anxiety‐like behaviour improved spatial and working memory. The treatment reduced forebrain A β plaque and MHC‐II antigen‐presenting microglial load. Additionally, EcN rha L‐DOPA increased protein levels of the dendritic spine marker PSD95. Conclusions and Implications: This translational study suggests that EcN rha L‐DOPA modifies AD by boosting brain catecholamine production, reducing A β accumulation and neuroinflammation, promoting synaptic health, and enhancing cognitive function. Collectively, these results highlight EcN rha L‐DOPA as a promising preclinical engineered gut microbiome‐based therapeutic strategy for early‐stage AD.
- Open Access
MicroRNA-181 influences Alzheimer’s risk by regulating neprilysin and microtubule-associated tau pathways, offering a novel target
Alzheimer’s disease (AD) is characterized by amyloid-β (Aβ) peptide plaques and neurofibrillary tangles from hyperphosphorylated tau, though factors linking amyloid and tau pathology remain unclear. We investigated whether microRNA-181d-5p (miR-181d) associates with AD-related brain changes and regulates neprilysin and tau. Modeling miR-181d across individuals with no cognitive impairment, mild cognitive impairment, and AD revealed region- and sex-specific associations. Higher miR-181d levels associated with greater AD probability in the temporal lobe and cerebellum, and lower probability in the posterior cingulate cortex of males; miR-181c attenuated these probabilities. SNPs near MIR181 associated with altered entorhinal cortical thickness. In cellular models, miR-181 reduced neprilysin 3′-UTR activity, mRNA, protein, and enzymatic activity, while increasing tau mRNA and protein. Neprilysin diminution impairs Aβ clearance and elevates tau, contributing to AD. RNA sequencing identified miR-181d-responsive neurodegenerative pathways. These findings identify miR-181 as a regulator of AD-relevant amyloid and tau pathways, providing novel targets. Teaser: MiRNA-181 is a key regulator of Alzheimer’s risk through its effects on neprilysin and tau proteins, a novel potential target.
Open AccessMicroRNA-181 influences Alzheimer’s risk by regulating neprilysin and microtubule-associated tau pathways, offering a novel target
Alzheimer’s disease (AD) is characterized by amyloid-β (Aβ) peptide plaques and neurofibrillary tangles from hyperphosphorylated tau, though factors linking amyloid and tau pathology remain unclear. We investigated whether microRNA-181d-5p (miR-181d) associates with AD-related brain changes and regulates neprilysin and tau. Modeling miR-181d across individuals with no cognitive impairment, mild cognitive impairment, and AD revealed region- and sex-specific associations. Higher miR-181d levels associated with greater AD probability in the temporal lobe and cerebellum, and lower probability in the posterior cingulate cortex of males; miR-181c attenuated these probabilities. SNPs near MIR181 associated with altered entorhinal cortical thickness. In cellular models, miR-181 reduced neprilysin 3′-UTR activity, mRNA, protein, and enzymatic activity, while increasing tau mRNA and protein. Neprilysin diminution impairs Aβ clearance and elevates tau, contributing to AD. RNA sequencing identified miR-181d-responsive neurodegenerative pathways. These findings identify miR-181 as a regulator of AD-relevant amyloid and tau pathways, providing novel targets. Teaser: MiRNA-181 is a key regulator of Alzheimer’s risk through its effects on neprilysin and tau proteins, a novel potential target.
- 20 April 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 111 (2) , 624-635
Psychometric criteria for superior cognitive performance in very old adults
Background: The cellular mechanisms that promote the maintenance of cognitive abilities in very old people designated as successful agers remain under-investigated. Here, we report an episodic memory performance-based criteria that differentiates superior cognitive function from normative cognitive function in adults aged 80 and older. Objective: Using this new criteria, we demonstrate how neuropathological and neurobiological underpinnings of superior cognitive performance can be investigated. Methods: The most recent verbal episodic memory WMS-R Logical Memory Delayed Recall (LM-DR) score was derived from 144 participants with no cognitive impairment (NCI) 80 years or older participants from the Rush Religious Orders Study classified with Superior Cognitive Performance (SCP, LM-DR ≥ 14) or Normal Cognitive Performance (NCP, LM-DR 13 ≥ 7). Both groups were compared on neuropathological measures for neuritic plaque (NP), diffuse plaque (DP), and neurofibrillary tangle (NFT) load. Results: NP (p = 0.44), DP (p = 0.27), and NFT (p = 0.28) burden did not differ between SCP and NCP cases. LM-DR scores did not correlate with NP (r = −0.08, p = 0.32), DP (r = −0.14, p = 0.07), or NFT (r = −0.12, p = 0.13) load. Biochemical analysis revealed significantly higher levels of heat-shock protein HSPB6 in SCP compared to NCP (p < 0.001). Conclusions: Heat shock protein differences were observed between NCP and SCP groups. This suggests that our proposed criteria for SCP can help identify neurobiological mechanisms of successful cognitive aging. Our SCP criteria are also concordant with the SuperAger criteria which supports the generalizability of the SCP criteria to other datasets.
- 20 April 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 111 (2) , 624-635
Psychometric criteria for superior cognitive performance in very old adults
Background: The cellular mechanisms that promote the maintenance of cognitive abilities in very old people designated as successful agers remain under-investigated. Here, we report an episodic memory performance-based criteria that differentiates superior cognitive function from normative cognitive function in adults aged 80 and older. Objective: Using this new criteria, we demonstrate how neuropathological and neurobiological underpinnings of superior cognitive performance can be investigated. Methods: The most recent verbal episodic memory WMS-R Logical Memory Delayed Recall (LM-DR) score was derived from 144 participants with no cognitive impairment (NCI) 80 years or older participants from the Rush Religious Orders Study classified with Superior Cognitive Performance (SCP, LM-DR ≥ 14) or Normal Cognitive Performance (NCP, LM-DR 13 ≥ 7). Both groups were compared on neuropathological measures for neuritic plaque (NP), diffuse plaque (DP), and neurofibrillary tangle (NFT) load. Results: NP (p = 0.44), DP (p = 0.27), and NFT (p = 0.28) burden did not differ between SCP and NCP cases. LM-DR scores did not correlate with NP (r = −0.08, p = 0.32), DP (r = −0.14, p = 0.07), or NFT (r = −0.12, p = 0.13) load. Biochemical analysis revealed significantly higher levels of heat-shock protein HSPB6 in SCP compared to NCP (p < 0.001). Conclusions: Heat shock protein differences were observed between NCP and SCP groups. This suggests that our proposed criteria for SCP can help identify neurobiological mechanisms of successful cognitive aging. Our SCP criteria are also concordant with the SuperAger criteria which supports the generalizability of the SCP criteria to other datasets.
- Open Access
- 27 January 2026
- Published by Springer Nature in Molecular Neurodegeneration Advances
- Vol. 2 (1)
Pretangle tau pathology accrual in the default mode network during the progression of Alzheimer’s disease
Alzheimer’s disease (AD) is a secondary tauopathy characterized by the accumulation of aggregated amyloid-beta (Aβ) peptides as extracellular ne
- 27 January 2026
- Published by Springer Nature in Molecular Neurodegeneration Advances
- Vol. 2 (1)
Open AccessPretangle tau pathology accrual in the default mode network during the progression of Alzheimer’s disease
Alzheimer’s disease (AD) is a secondary tauopathy characterized by the accumulation of aggregated amyloid-beta (Aβ) peptides as extracellular ne
- Open Access
- 27 October 2025
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 13 (1) , 1-22
Neuronal gene profiling of tau oligomer-bearing cholinergic nucleus basalis neurons during the onset of Alzheimer’s disease
Soluble tau oligomeric assemblies display neurotoxic properties and may provide a pathogenic link between neurofibrillary tangle evolution and selective neuronal vulnerability in Alzheimer’s disease (AD). However, the precise molecular and cellular pathways mediating tau oligomer toxicity are unclear. We combined single-neuron laser capture microdissection with custom microarrays to investigate differences in the molecular signatures of basal forebrain neurons within the nucleus basalis of Meynert (nbM) labeled for p75NTR, a cholinergic cell marker, or dual-labeled for p75NTR and TOC1, a tau oligomer marker. Tissue was obtained postmortem from Rush Religious Orders Study participants who died with an antemortem clinical diagnosis of no cognitive impairment (NCI), mild cognitive impairment (MCI), or mild/moderate AD. Using clinical diagnosis as a covariate to isolate tau oligomer-specific mechanisms, we identified 140 differentially expressed genes (DEGs) in p75NTR + /TOC1 + cholinergic nbM neurons compared to p75NTR + /TOC1- neurons. STRING interactome and pathway analysis revealed that downregulated genes were associated with pre- and postsynaptic function, with additional enrichment in glutamate and acetylcholine signaling. By contrast, upregulated genes related to cellular stress responses and apoptosis were clustered with a subset of downregulated DEGs regulating mitochondrial metabolism and redox function, indicative of bioenergetic failure. Weighted gene co-expression correlation network analysis of the entire dataset revealed only two significantly correlated modules, which were either negatively correlated with the presence of TOC1 and enriched for synaptic signaling or positively correlated with TOC1 and enriched for cellular responses to hypoxia. These data show with single-neuron resolution that oligomeric tau formation in vulnerable cholinergic nbM neurons, even prior to MCI, is associated with the dysregulation of multiple classes of genes driving cell/mitochondrial stress and synaptic imbalances, which may be amenable for disease-modifying therapeutic approaches.
- 27 October 2025
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 13 (1) , 1-22
Open AccessNeuronal gene profiling of tau oligomer-bearing cholinergic nucleus basalis neurons during the onset of Alzheimer’s disease
Soluble tau oligomeric assemblies display neurotoxic properties and may provide a pathogenic link between neurofibrillary tangle evolution and selective neuronal vulnerability in Alzheimer’s disease (AD). However, the precise molecular and cellular pathways mediating tau oligomer toxicity are unclear. We combined single-neuron laser capture microdissection with custom microarrays to investigate differences in the molecular signatures of basal forebrain neurons within the nucleus basalis of Meynert (nbM) labeled for p75NTR, a cholinergic cell marker, or dual-labeled for p75NTR and TOC1, a tau oligomer marker. Tissue was obtained postmortem from Rush Religious Orders Study participants who died with an antemortem clinical diagnosis of no cognitive impairment (NCI), mild cognitive impairment (MCI), or mild/moderate AD. Using clinical diagnosis as a covariate to isolate tau oligomer-specific mechanisms, we identified 140 differentially expressed genes (DEGs) in p75NTR + /TOC1 + cholinergic nbM neurons compared to p75NTR + /TOC1- neurons. STRING interactome and pathway analysis revealed that downregulated genes were associated with pre- and postsynaptic function, with additional enrichment in glutamate and acetylcholine signaling. By contrast, upregulated genes related to cellular stress responses and apoptosis were clustered with a subset of downregulated DEGs regulating mitochondrial metabolism and redox function, indicative of bioenergetic failure. Weighted gene co-expression correlation network analysis of the entire dataset revealed only two significantly correlated modules, which were either negatively correlated with the presence of TOC1 and enriched for synaptic signaling or positively correlated with TOC1 and enriched for cellular responses to hypoxia. These data show with single-neuron resolution that oligomeric tau formation in vulnerable cholinergic nbM neurons, even prior to MCI, is associated with the dysregulation of multiple classes of genes driving cell/mitochondrial stress and synaptic imbalances, which may be amenable for disease-modifying therapeutic approaches.
- Open Access
- 14 September 2025
- Published by Wiley in Proteomics
- Vol. 26 (4) , 23-35
Coupling CZE, Liquid‐Phase Ion Mobility, to MS/MS for Quantitative Top‐Down Proteomics: Revealing Significant Proteoform Differences Between Healthy and Alzheimer's Disease Brains
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline and pathological protein aggregation. Comprehensive quantitative proteomics of brain tissues from AD patients is critical for pursuing a better understanding of the molecular mechanisms that drive AD progression. Here, we present one of the first quantitative top‐down proteomics (TDP) studies of postmortem cortex samples from AD patients and healthy controls to profile their proteoform differences by coupling capillary zone electrophoresis (CZE, liquid‐phase ion mobility) to tandem mass spectrometry (MS/MS). We identified 3191 unique proteoforms and uncovered a drastic transformation in the proteoform profile in AD compared to healthy controls. Over 2200 proteoforms were exclusively identified in either AD or healthy control samples, and 157 proteoforms identified in both AD and control samples showed statistically significant abundance differences between the two conditions. Gene Ontology and pathway analysis of the genes associated with those proteoforms revealed broad changes in biological processes in AD brains, for example, telomere organization, substantia nigra development, amyloid fibril formation, microtubule cytoskeleton organization, progressive neurological disorders, long‐term synaptic potentiation, and axogenesis. These biological processes are highly associated with the development of AD. Our study revealed a pool of potential novel proteoform biomarkers of AD in human brain samples for early diagnosis and therapy development. Summary: Alzheimer's disease (AD) is a chronic neurodegenerative disease, destroying brain cells and causing thinking ability and memory to decline over time. Proteins (e.g., amyloid and tau) play key roles in the development of AD. Global and accurate protein measurement of human brains of AD patients and healthy controls will shed new light on the molecular mechanisms driving AD progression and discover new biomarkers for AD diagnosis and therapeutic development. Here, we performed the first CZE‐MS/MS‐based quantitative top‐down proteomics (TDP) of a small cohort of AD human brain samples and healthy controls (5 AD and 5 control) to determine the differentially quantified proteoforms between the two health conditions. Over 3000 proteoforms were identified, and only about 700 proteoforms were detected in both conditions, indicating drastically different proteoform profiles between the two conditions. The differentially quantified proteoforms (e.g., tau, neurogranin, and calmodulin‐1 proteoforms) are associated with biological processes relevant to AD development, for example, amyloid fibril formation, microtubule disruption, synaptic transmission, and axogenesis. The results offer a deep view of the proteoform transformation in the AD human brain compared to the healthy control, providing potential proteoform biomarkers for AD diagnosis and proteoform targets for therapeutic development.
- 14 September 2025
- Published by Wiley in Proteomics
- Vol. 26 (4) , 23-35
Open AccessCoupling CZE, Liquid‐Phase Ion Mobility, to MS/MS for Quantitative Top‐Down Proteomics: Revealing Significant Proteoform Differences Between Healthy and Alzheimer's Disease Brains
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline and pathological protein aggregation. Comprehensive quantitative proteomics of brain tissues from AD patients is critical for pursuing a better understanding of the molecular mechanisms that drive AD progression. Here, we present one of the first quantitative top‐down proteomics (TDP) studies of postmortem cortex samples from AD patients and healthy controls to profile their proteoform differences by coupling capillary zone electrophoresis (CZE, liquid‐phase ion mobility) to tandem mass spectrometry (MS/MS). We identified 3191 unique proteoforms and uncovered a drastic transformation in the proteoform profile in AD compared to healthy controls. Over 2200 proteoforms were exclusively identified in either AD or healthy control samples, and 157 proteoforms identified in both AD and control samples showed statistically significant abundance differences between the two conditions. Gene Ontology and pathway analysis of the genes associated with those proteoforms revealed broad changes in biological processes in AD brains, for example, telomere organization, substantia nigra development, amyloid fibril formation, microtubule cytoskeleton organization, progressive neurological disorders, long‐term synaptic potentiation, and axogenesis. These biological processes are highly associated with the development of AD. Our study revealed a pool of potential novel proteoform biomarkers of AD in human brain samples for early diagnosis and therapy development. Summary: Alzheimer's disease (AD) is a chronic neurodegenerative disease, destroying brain cells and causing thinking ability and memory to decline over time. Proteins (e.g., amyloid and tau) play key roles in the development of AD. Global and accurate protein measurement of human brains of AD patients and healthy controls will shed new light on the molecular mechanisms driving AD progression and discover new biomarkers for AD diagnosis and therapeutic development. Here, we performed the first CZE‐MS/MS‐based quantitative top‐down proteomics (TDP) of a small cohort of AD human brain samples and healthy controls (5 AD and 5 control) to determine the differentially quantified proteoforms between the two health conditions. Over 3000 proteoforms were identified, and only about 700 proteoforms were detected in both conditions, indicating drastically different proteoform profiles between the two conditions. The differentially quantified proteoforms (e.g., tau, neurogranin, and calmodulin‐1 proteoforms) are associated with biological processes relevant to AD development, for example, amyloid fibril formation, microtubule disruption, synaptic transmission, and axogenesis. The results offer a deep view of the proteoform transformation in the AD human brain compared to the healthy control, providing potential proteoform biomarkers for AD diagnosis and proteoform targets for therapeutic development.
- Open Access
- 24 August 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (8) , e70399
MicroRNA‐153‐3p targets repressor element 1‐silencing transcription factor (REST) and neuronal differentiation: Implications for Alzheimer's disease
INTRODUCTION: Small non‐coding microRNAs (miRNAs) play essential roles in Alzheimer's disease (AD) pathogenesis. Repressor element 1‐silencing transcription factor (REST) is involved in AD, though its regulation remains unclear.METHODS: We performed real‐time quantitative polymerase chain reaction (qPCR) in autopsied brain tissues to determine miR‐153‐3p and AD associations. A reporter‐based assay measured the activity of REST mRNA 3′‐untranslated region (3′‐UTR). Induced pluripotent stem cells (iPSC)‐derived neurons and human cell lines were applied to determine miR‐153‐3p regulation of endogenous proteins.RESULTS: Elevation of miR‐153‐3p is associated with a reduced probability of AD, while elevated REST is associated with a greater probability of AD. The 3′‐UTR functional assay pinpointed the miR‐153‐3p binding sites. miR‐153‐3p treatment reduced REST, amyloid precursor protein (APP), and α‐synuclein (SNCA) 3′‐UTR activities and protein levels. miR‐153‐3p treatment altered REST and neuronal differentiation in iPSC‐derived neuronal stem cells. RNA‐sequencing and proteomics revealed miR‐153‐3p‐associated networks.DISCUSSION: miR‐153‐3p reduces REST, APP, and SNCA expression, pointing toward its therapeutic and biomarker potential in neurodegenerative diseases.Highlights: With the increased emphasis on comorbidities of Alzheimer's disease (AD) and other neurodegenerative diseases, we identified that miR‐153‐3p, as a master regulator, reduced a group of neurodegeneration related proteins: REST, amyloid precursor protein (APP) and α‐synuclein (SNCA) levels. The elevation of miR‐153‐3p levels is associated with reduced probability of AD in posterior cingulate cortex (PCC), while REST, by contrast, is associated with a greater probability of AD. miR‐153‐3p treatment alters REST protein levels and neuronal differentiation in induced pluripotent stem cells (iPSC) derived neuronal cells. RNA sequencing proteomics and interactome analysis revealed the role of miR‐153‐3p in axonal guidance.
- 24 August 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (8) , e70399
Open AccessMicroRNA‐153‐3p targets repressor element 1‐silencing transcription factor (REST) and neuronal differentiation: Implications for Alzheimer's disease
INTRODUCTION: Small non‐coding microRNAs (miRNAs) play essential roles in Alzheimer's disease (AD) pathogenesis. Repressor element 1‐silencing transcription factor (REST) is involved in AD, though its regulation remains unclear.METHODS: We performed real‐time quantitative polymerase chain reaction (qPCR) in autopsied brain tissues to determine miR‐153‐3p and AD associations. A reporter‐based assay measured the activity of REST mRNA 3′‐untranslated region (3′‐UTR). Induced pluripotent stem cells (iPSC)‐derived neurons and human cell lines were applied to determine miR‐153‐3p regulation of endogenous proteins.RESULTS: Elevation of miR‐153‐3p is associated with a reduced probability of AD, while elevated REST is associated with a greater probability of AD. The 3′‐UTR functional assay pinpointed the miR‐153‐3p binding sites. miR‐153‐3p treatment reduced REST, amyloid precursor protein (APP), and α‐synuclein (SNCA) 3′‐UTR activities and protein levels. miR‐153‐3p treatment altered REST and neuronal differentiation in iPSC‐derived neuronal stem cells. RNA‐sequencing and proteomics revealed miR‐153‐3p‐associated networks.DISCUSSION: miR‐153‐3p reduces REST, APP, and SNCA expression, pointing toward its therapeutic and biomarker potential in neurodegenerative diseases.Highlights: With the increased emphasis on comorbidities of Alzheimer's disease (AD) and other neurodegenerative diseases, we identified that miR‐153‐3p, as a master regulator, reduced a group of neurodegeneration related proteins: REST, amyloid precursor protein (APP) and α‐synuclein (SNCA) levels. The elevation of miR‐153‐3p levels is associated with reduced probability of AD in posterior cingulate cortex (PCC), while REST, by contrast, is associated with a greater probability of AD. miR‐153‐3p treatment alters REST protein levels and neuronal differentiation in induced pluripotent stem cells (iPSC) derived neuronal cells. RNA sequencing proteomics and interactome analysis revealed the role of miR‐153‐3p in axonal guidance.
- Open Access
Burnout in nurses and biomarkers of stress, inflammation and neuroplasticity
Burnout is an occupational challenge to the health, performance, and retention of healthcare personnel. The objective of this cross-sectional study was to further our understanding of the association between burnout, work, coping, and cognitive impairment as it relates to neuroendocrine, inflammatory, and neuroplastic disease mechanisms. One hundred hospital- based registered nurses responded to a validated survey addressing employment and work characteristics, coping, and cognitive impairment, and a one-item, burnout scale. In addition, they all provided blood samples. Nineteen percent of the nurses reported symptoms of evolving burnout and an additional 12% reported established burnout. Severity of burnout was inversely associated with self-rated energy (p<.001), ability to concentrate (p<.001), and positively associated with stressed at work (p<.001), but not with workplace cognitive impairment. The anti-inflammatory and pro-energetic biomarker interleukin-10 was elevated in respondents in the combined two highest burnout categories (mean 2.81, S.E.M. 0.26 pg/mL) vs. a median of 2.09 pg/mL in the no-burnout category (p<.02). When biomarkers in blood were regressed on severity of burnout, concentration of the anabolic hormone dehydroepiandrosterone-sulfate (standardized beta -.73, p=.007) and the neuronal strain biomarker neurofilament light chain (-.79, p=.01) inversely predicted burnout. In contrast, the ability to cope with a tough situation at work was positively associated with burnout (.75, p=.02). The study not only confirms the association between burnout and self-reported individual and work-related adverse outcomes but, importantly, burnout-relevant neuroendocrine, inflammatory, and neuronal biomarkers. Nurses suffering from burnout might exhibit dysfunctional coping resulting in decreased recognition of low energy, which accelerates the burnout process. It is proposed that assessment of biological disease mechanisms should play a larger role in both scholarly and clinical burnout work.
Open AccessBurnout in nurses and biomarkers of stress, inflammation and neuroplasticity
Burnout is an occupational challenge to the health, performance, and retention of healthcare personnel. The objective of this cross-sectional study was to further our understanding of the association between burnout, work, coping, and cognitive impairment as it relates to neuroendocrine, inflammatory, and neuroplastic disease mechanisms. One hundred hospital- based registered nurses responded to a validated survey addressing employment and work characteristics, coping, and cognitive impairment, and a one-item, burnout scale. In addition, they all provided blood samples. Nineteen percent of the nurses reported symptoms of evolving burnout and an additional 12% reported established burnout. Severity of burnout was inversely associated with self-rated energy (p<.001), ability to concentrate (p<.001), and positively associated with stressed at work (p<.001), but not with workplace cognitive impairment. The anti-inflammatory and pro-energetic biomarker interleukin-10 was elevated in respondents in the combined two highest burnout categories (mean 2.81, S.E.M. 0.26 pg/mL) vs. a median of 2.09 pg/mL in the no-burnout category (p<.02). When biomarkers in blood were regressed on severity of burnout, concentration of the anabolic hormone dehydroepiandrosterone-sulfate (standardized beta -.73, p=.007) and the neuronal strain biomarker neurofilament light chain (-.79, p=.01) inversely predicted burnout. In contrast, the ability to cope with a tough situation at work was positively associated with burnout (.75, p=.02). The study not only confirms the association between burnout and self-reported individual and work-related adverse outcomes but, importantly, burnout-relevant neuroendocrine, inflammatory, and neuronal biomarkers. Nurses suffering from burnout might exhibit dysfunctional coping resulting in decreased recognition of low energy, which accelerates the burnout process. It is proposed that assessment of biological disease mechanisms should play a larger role in both scholarly and clinical burnout work.